<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511862</url>
  </required_header>
  <id_info>
    <org_study_id>G040148</org_study_id>
    <nct_id>NCT00511862</nct_id>
  </id_info>
  <brief_title>TheraSphere for the Treatment of Liver Metastases</brief_title>
  <official_title>TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer, Neuroendocrine Cancer or Non-colorectal/Non-neuroendocrine Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere
      treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with
      metastatic disease to the liver that cannot be treated or is progressing following treatment
      with systemic or other liver-directed therapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST)</measure>
    <time_frame>From the date of first treatment until date of first documented progression; median patient follow-up 30 months</time_frame>
    <description>Progression per RECIST v 1.0 is defined as at least 20% increase in the sum of the longest diameter of target lesions, taking as the reference the smallest sum of longest diameters recorded since treatment started, or unequivocal progression of existing non-target lesion or appearance of new lesions. A maximum of 5 target lesions per organ are assessed. To assess the impact of a non-systemic local therapy on progression, for the purposes of this trial, hepatic progression was defined as at least a 20% increase in the sum of the longest diameter of target hepatic lesions. Hepatic progression-free survival is the time from the day of first treatment with TheraSphere to determination of hepatic progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from first TheraSphere treatment to death; median follow up 30 months</time_frame>
    <description>Duration of survival from date of first TheraSphere treatment to date of death or censored to last known date alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Carcinoma, Neuroendocrine</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>TheraSphere</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Yttrium 90 glass microspheres</intervention_name>
    <description>120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe</description>
    <arm_group_label>TheraSphere</arm_group_label>
    <other_name>TheraSphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  diagnosis of metastatic disease to the liver that is refractory to, or inappropriate
             for, other systemic or liver-directed therapies

          -  unresectable liver metastases

          -  target tumors measurable using standard imaging techniques

          -  tumor replacement &lt; or = 50% of total liver volume (visual estimation by investigator)

          -  Hypervascular tumors (visual estimation by investigator)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

          -  minimum one month since most recent prior cancer therapy with the exception of
             patients receiving Sandostatin for neuroendocrine cancer

          -  patient informed consent

        Exclusion Criteria:

          -  At risk of hepatic or renal failure within 21 days of treatment (serum creatinine &gt;
             2.0 mg/dL unless on dialysis; serum bilirubin â‰¥ 2.0 mg/dL; albumin &lt; 2.0 mg/dL or any
             history of hepatic encephalopathy)

          -  contraindications to angiography and selective visceral catheterization including any
             non-correctable bleeding diathesis or coagulopathy, severe peripheral vascular disease
             or history of non-management allergy or intolerance to contrast, narcotics, sedatives
             or atropine

          -  severe liver dysfunction or presentation of pulmonary insufficiency or clinically
             evident history of chronic obstructive pulmonary disease

          -  cirrhosis or portal hypertension

          -  prior external beam radiation treatment to the liver

          -  prior TheraSphere treatment to the liver

          -  any intervention for, or compromise of the Ampulla of Vater

          -  clinically evident ascites (trace ascites on imaging is acceptable)

          -  any continuing complications of prior cancer therapy that have not improved or
             resolved prior to 21 days before first TheraSphere treatment

          -  significant life-threatening extrahepatic disease in judgment of physician

          -  concurrent enrollment in another study

          -  alternative available therapies in judgement of physician

          -  evidence on technetium-99m macroaggregated albumin scan that shows lung shunting &gt; 30
             Gy cumulative limit

          -  evidence on technetium-99m macroaggregated albumin scan showing potential for
             deposition of microspheres to the gastrointestinal tract that cannot be eliminated by
             catheter placement or corrective action using standard angiographic techniques

          -  positive serum pregnancy test in women of childbearing potential

          -  co-morbid disease or condition that puts the patient at undue risk or precludes use of
             TheraSphere in judgment of physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Al Benson III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital, Robert H Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-4010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <results_first_submitted>October 17, 2013</results_first_submitted>
  <results_first_submitted_qc>April 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2014</results_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TheraSphere</keyword>
  <keyword>radioactive microspheres</keyword>
  <keyword>Yttrium-90</keyword>
  <keyword>Yttrium glass microspheres</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>151 patients recruited from January 19, 2007 to October 7, 2009</recruitment_details>
      <pre_assignment_details>Patients were assigned to groups on the basis of type of primary cancer - colorectal cancer; neuroendocrine cancer or non-colorectal/non-neuroendocrine. Subjects who unable to receive TheraSphere (target dose 120 Gy) due to vascular shunting to the lungs or GI tract were not enrolled in the study and did not receive yttrium 90 glass microspheres.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Colorectal Cancer</title>
          <description>Colorectal cancer patients with liver metastatic disease, refractory to standard of care therapy who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
        </group>
        <group group_id="P2">
          <title>Neuroendocrine Cancer</title>
          <description>Neuroendocrine cancer patients with liver metastatic disease, refractory to standard of care therapy who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
        </group>
        <group group_id="P3">
          <title>Non-Colorectal/Non-neuroendocrine</title>
          <description>Patients with liver metastatic disease not arising from colorectal cancer or neuroendocrine cancer, refractory to standard of care therapy who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects treated with TheraSphere were enrolled and assigned to groups based on their primary cancer type. The total population and each subgroup population was analyzed for safety, progression and survival endpoints. In the neuroendocrine group, a median overall survival was not achieved so a post-hoc analysis of 2 year survival was performed.</population>
      <group_list>
        <group group_id="B1">
          <title>Colorectal Cancer</title>
          <description>colorectal cancer patients with liver metastatic disease, refractory to standard of care therapy</description>
        </group>
        <group group_id="B2">
          <title>Neuroendocrine Cancer</title>
          <description>neuroendocrine cancer patients with liver metastatic disease, refractory to standard of care therapy</description>
        </group>
        <group group_id="B3">
          <title>Non-Colorectal/Non-neuroendocrine</title>
          <description>patients with liver metastatic disease not arising from colorectal cancer or neuroendocrine cancer, refractory to standard of care therapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="10.92"/>
                    <measurement group_id="B2" value="61.8" spread="13.71"/>
                    <measurement group_id="B3" value="66.1" spread="8.52"/>
                    <measurement group_id="B4" value="63.7" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST)</title>
        <description>Progression per RECIST v 1.0 is defined as at least 20% increase in the sum of the longest diameter of target lesions, taking as the reference the smallest sum of longest diameters recorded since treatment started, or unequivocal progression of existing non-target lesion or appearance of new lesions. A maximum of 5 target lesions per organ are assessed. To assess the impact of a non-systemic local therapy on progression, for the purposes of this trial, hepatic progression was defined as at least a 20% increase in the sum of the longest diameter of target hepatic lesions. Hepatic progression-free survival is the time from the day of first treatment with TheraSphere to determination of hepatic progression.</description>
        <time_frame>From the date of first treatment until date of first documented progression; median patient follow-up 30 months</time_frame>
        <population>Patients receiving at least one TheraSphere treatment with images evaluable by RECIST</population>
        <group_list>
          <group group_id="O1">
            <title>Colorectal Cancer</title>
            <description>Colorectal cancer patients with liver metastatic disease, refractory to standard of care therapy who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Neuroendocrine Cancer</title>
            <description>Neuroendocrine cancer patients with liver metastatic disease, refractory to standard of care therapy who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Non-Colorectal/Non-neuroendocrine</title>
            <description>Patients with liver metastatic disease not arising from colorectal cancer or neuroendocrine cancer, refractory to standard of care therapy who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
          </group>
          <group group_id="O4">
            <title>All Patients</title>
            <description>All patients in colorectal cancer, neuroendocrine cancer and non-colorectal/non-neuroendocrine groups</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST)</title>
          <description>Progression per RECIST v 1.0 is defined as at least 20% increase in the sum of the longest diameter of target lesions, taking as the reference the smallest sum of longest diameters recorded since treatment started, or unequivocal progression of existing non-target lesion or appearance of new lesions. A maximum of 5 target lesions per organ are assessed. To assess the impact of a non-systemic local therapy on progression, for the purposes of this trial, hepatic progression was defined as at least a 20% increase in the sum of the longest diameter of target hepatic lesions. Hepatic progression-free survival is the time from the day of first treatment with TheraSphere to determination of hepatic progression.</description>
          <population>Patients receiving at least one TheraSphere treatment with images evaluable by RECIST</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="5.8"/>
                    <measurement group_id="O2" value="17.9" lower_limit="13.5" upper_limit="19.5"/>
                    <measurement group_id="O3" value="2.9" lower_limit="1.3" upper_limit="3.3"/>
                    <measurement group_id="O4" value="3.4" lower_limit="3.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Duration of survival from date of first TheraSphere treatment to date of death or censored to last known date alive.</description>
        <time_frame>Time from first TheraSphere treatment to death; median follow up 30 months</time_frame>
        <population>In the neuroendocrine group, a median overall survival was not achieved so a post-hoc analysis of 2 year survival was performed in Outcome Measure 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Colorectal Cancer</title>
            <description>Colorectal cancer patients with liver metastatic disease, refractory to standard of care therapy who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Non Colorectal/Non-Neuroendocrine</title>
            <description>Patients with metastatic liver disease arising from primary cancers other than colorectal or neuroendocrine cancer who received intrahepatic TheraSphere yttrium-90 glass microspheres (target dose 120 Gy) on Day 0</description>
          </group>
          <group group_id="O3">
            <title>All Patients</title>
            <description>All patients in colorectal cancer, neuroendocrine cancer and non-colorectal/non-neuroendocrine groups</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Duration of survival from date of first TheraSphere treatment to date of death or censored to last known date alive.</description>
          <population>In the neuroendocrine group, a median overall survival was not achieved so a post-hoc analysis of 2 year survival was performed in Outcome Measure 3.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="6.6" upper_limit="11.9"/>
                    <measurement group_id="O2" value="10.4" lower_limit="6.6" upper_limit="14.6"/>
                    <measurement group_id="O3" value="13.6" lower_limit="11.1" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>2 Year Survival</title>
        <description>The percentage of patients in the neuroendocrine group alive at 2 years</description>
        <time_frame>24 months from treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neuroendocrine Cancer</title>
            <description>neuroendocrine cancer patients with liver metastatic disease, refractory to standard of care therapy</description>
          </group>
        </group_list>
        <measure>
          <title>2 Year Survival</title>
          <description>The percentage of patients in the neuroendocrine group alive at 2 years</description>
          <units>percentage of treated subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events collected for 3 months, device-related adverse events captured to month 18</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TheraSphere</title>
          <description>total population receiving at least one TheraSphere treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>GI hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Esophagial varices</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>GI ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vessel injury - lower extremity artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal or epigastric pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT &gt; ULN</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>AST &gt;ULN</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase &gt;ULN</sub_title>
                <counts group_id="E1" events="56" subjects_affected="56" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bilirubin &gt;ULN</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia &lt; LLN</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>BTG International Canada Inc.</organization>
      <phone>613-801-1880</phone>
      <email>TheraSphereClinical@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

